

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/136986 A2

(51) International Patent Classification:
Not classified

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2024/060580

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
17 December 2024 (17.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/611,673 18 December 2023 (18.12.2023) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 450
Water Street, Cambridge, Massachusetts 02141 (US).

(72) Inventors: **LHULLIER, Claire**; c/o Genzyme Corpora-
tion, 450 Water Street, Cambridge, Massachusetts 02141
(US). **BEIL, Christian**; c/o Genzyme Corporation, 450
Water Street, Cambridge, Massachusetts 02141 (US).
AMENGUAL RIGO, José Antonio; c/o Genzyme Corpo-
ration, 450 Water Street, Cambridge, Massachusetts 02141
(US). **QIU, Yu**; c/o Genzyme Corporation, 450 Water
Street, Cambridge, Massachusetts 021241 (US). **LI, Xiang-
ming**; c/o Genzyme Corporation, 450 Water Street, Cam-
bridge, Massachusetts 02141 (US).

(74) Agent: **VELEMA, James H.** et al.; LATHROP GPM LLP,
28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: IL-12 LOSS OF POTENCY MUTEINS

(57) Abstract: The present invention provides pharmaceutical compositions comprising IL-12 muteins, isolated nucleic acids encoding the muteins, vectors, and host cells containing the same, and methods or uses of such compositions for the treatment of a disease or disorder.

WO 2025/136986 A2